Morgan Stanley raised the firm’s price target on Roche (RHHBY) to CHF 312 from CHF 305 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- H.C. Wainwright sees increased uncertainty for Sarepta franchise
- Roche’s Genentech present data on trontinemab, Elecsys plasma test
- Sarepta study pause brings approvability risk in Europe, says RBC
- EMA put clinical hold on Roche, Sarepta DMD studies after death
- TG Therapeutics price target raised to $11 from $10 at BofA